CRL · Charles River Laboratories International, Inc.
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP operating margin non-GAAP | 16.3% | Q1 FY2026 | — |
| Organic revenue growth non-GAAP | -1.5% | Q1 FY2026 | — |
| Organic revenue growth (DSA segment) non-GAAP | -1.4% | Q1 FY2026 | — |
| Organic revenue growth (Manufacturing segment) non-GAAP | 2.9% | Q1 FY2026 | — |
| Organic revenue growth (RMS segment) non-GAAP | -5.5% | Q1 FY2026 | — |
| DSA net book-to-bill | 1.1 | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRL
this stock
Charles River Laboratories International, Inc.
|
$10.81B | +12.5% | +10.5% | — | 9.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$197.88B | -8.0% | +0.4% | 29.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$144.26B | -10.6% | +8.5% | 39.4 | 1.5% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.76B | -16.1% | +10.4% | 41.8 | 2.5% |
|
NTRA
Natera, Inc.
|
$38.87B | +18.5% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRL | -3.9% | +23.0% | +2.2% | -1.1% | +12.5% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -2.3% | +22.7% | -5.7% | -0.6% | +3.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.